Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial

BACKGROUND: Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid–rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization’s (WHO) END TB Strategy. However, there are few data on 3HP patient acceptanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Semitala, Fred C., Kadota, Jillian L., Musinguzi, Allan, Nabunje, Juliet, Welishe, Fred, Nakitende, Anne, Akello, Lydia, Bishop, Opira, Patel, Devika, Sammann, Amanda, Nahid, Payam, Belknap, Robert, Kamya, Moses R., Handley, Margaret A., Phillips, Patrick P. J., Katahoire, Anne, Berger, Christopher A., Kiwanuka, Noah, Katamba, Achilles, Dowdy, David W., Cattamanchi, Adithya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726462/
https://www.ncbi.nlm.nih.gov/pubmed/34914696
http://dx.doi.org/10.1371/journal.pmed.1003875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726462/
https://www.ncbi.nlm.nih.gov/pubmed/34914696
http://dx.doi.org/10.1371/journal.pmed.1003875

Ejemplares similares